JCJoshua R. Cox

Joshua R. Cox

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joshua R. Cox has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Joanne E. Konkel

    Lydia Becker Institute of Immunology and Inflammation, School of Biological Sciences, Faculty of Biology, Medicine and Health Manchester Academic Health Science Centre, University of Manchester Manchester UK

    5 shared publications
  • Kelly Wemyss

    Lydia Becker Institute of Immunology and Inflammation Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

    4 shared publications
  • Amy Saunders

    Manchester Collaborative Centre for Inflammation Research

    3 shared publications
  • Holly Linley

    Manchester Collaborative Centre for Inflammation Research

    3 shared publications
  • Lucy Buckingham

    Lydia Becker Institute of Immunology and Inflammation, Division of Infection, Immunity and Respiratory Medicine, School of Biological Science, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre , Manchester M13 9PL

    3 shared publications
  • Megan J. Priestley

    Manchester Cell-Matrix Centre, Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9PT, UK

    3 shared publications

Latest Publications

  • Open Access

    Specific Deletion of Interleukin‐1 Beta in Microglia Improves Acute Outcome and Modulates Neurogenesis After Ischemic Stroke

    by Alba Grayston, Margarida Baptista, Kelly Wemyss, Ruby Taylor, Grace Cullen, Syeda S. Jafree, Nadim Luka, Joshua R. Cox, Joanne E. Konkel, David Brough, et al.

    Interleukin‐1 (IL‐1) signaling is a major driver of post‐ischemic neuroinflammation, yet the cell‐ and isoform‐specific roles of the two major IL‐1 receptor type 1 agonists, IL‐1α and IL‐1β, remain incompletely defined in the context of stroke. Microglia rapidly express IL‐1α after cerebral ischemia, whereas IL‐1β expression is delayed and restricted to a small subset of microglia and infiltrating immune cells. Here, we investigated for the first time the specific contribution of microglial‐derived IL‐1β to acute injury and post‐stroke neurorepair after transient middle cerebral artery occlusion in male and female mice, through microglial‐specific tamoxifen‐inducible Cre‐loxP‐mediated recombination. Deletion of microglial IL‐1β improved acute neurological outcomes, reduced neutrophil accumulation in the ischemic brain, and dampened systemic inflammatory cytokines. These effects were most evident during the acute phase and in females in mice. In contrast, long‐term functional recovery was largely unaffected. However, microglial IL‐1β deletion differentially regulated post‐stroke neurogenesis, enhancing subventricular zone neurogenic responses and ectopic neuroblast migration while limiting hippocampal neurogenesis. Together, these findings identify microglial IL‐1β as a key amplifier of early inflammatory injury after stroke, exerting region‐specific effects on neurogenic niches, and highlight distinct, non‐redundant roles for microglial IL‐1 isoforms in ischemic brain injury and repair.


  • Open Access

    CD200R1 promotes the development of murine γδ17 T cells

    by Holly Linley, Shafqat Jaigirdar, Lucy Buckingham, Joshua Cox, Megan Priestley, Anna Hains, Amy Saunders

    γδ T cells are enriched at barrier sites such as skin, gut, and lung, where they protect against cancer and infections, and promote healing. They detect diverse ligands in T-cell receptor–dependent or independent manners, producing large quantities of pro-inflammatory cytokines. γδ T cells develop in fetal thymi in temporally controlled waves where, unlike αβ T cells, many γδ T cells adopt their effector fate, becoming either IFN-γ or IL-17A producers (γδ17 T cells). CD200R1 suppresses myeloid cell activity but has also been shown to promote innate lymphoid cell IL-17A production, enhancing psoriasis-like skin inflammation. γδ17 T cells are potent IL-17A producers in skin. Therefore, the effect of CD200R1 on IL-17A production by γδ17 T cells was investigated using CD200R1KO mice. CD200R1 was revealed to promote IL-17A production by γδ T cells in skin and lymphoid organs. Although CD200R1 is not expressed by adult γδ T cells, it is expressed by immature developing γδ T cells in fetal thymus, where it supports the development of γδ17 T cells, enhancing γδ17 T-cell and RORγt+ γδ T-cell numbers in fetal thymic organ cultures. This identifies CD200R1 as an important novel regulator of γδ17 T-cell development in early life, a key process for ensuring immunity, particularly at barrier sites.

  • Open Access

    Specific deletion of interleukin-1 beta in microglia improves acute outcome and modulates neurogenesis after ischemic stroke

    by Alba Grayston, Margarida Baptista, Kelly Wemyss, Ruby Taylor, Grace Cullen, Syeda S Jafree, Nadim Luka, Joshua R Cox, Joanne E Konkel, David Brough, et al.

    Interleukin-1 (IL-1) signaling is a major driver of post-ischemic neuroinflammation, yet the cell- and isoform-specific roles of the two major IL-1 receptor type 1 agonists, IL-1α and IL-1β, remain incompletely defined in the context of stroke. Microglia rapidly express IL-1α after cerebral ischemia, whereas IL-1β expression is delayed and restricted to a small subset of microglia and infiltrating immune cells. Here, we investigated for the first time the specific contribution of microglial-derived IL-1β to acute injury and post-stroke neurorepair after transient middle cerebral artery occlusion in male and female mice, through microglial-specific tamoxifen-inducible Cre-loxP-mediated recombination. Deletion of microglial IL-1β improved acute neurological outcome, reduced neutrophil accumulation in the ischemic brain and dampened systemic inflammatory cytokines. These effects were most evident during the acute phase and in female in mice. In contrast, long-term functional recovery was largely unaffected. However, microglial IL-1β deletion differentially regulated post-stroke neurogenesis, enhancing subventricular zone neurogenic responses and ectopic neuroblast migration while limiting hippocampal neurogenesis. Together, these findings identify microglial IL-1β as a key amplifier of early inflammatory injury after stroke, exerting region-specific effects on neurogenic niches, and highlight distinct, non-redundant roles for microglial IL-1 isoforms in ischemic brain injury and repair.


  • Open Access

    TGFβ Plays a Minimal Role in Supporting Th17 Cell Phenotype Post Differentiation

    by Annie Whelan, Kelly Wemyss, Joshua R. Cox, Rufus Daw, Flora A. McClure, James I. King, Logan Sauers, Hayley M. Bridgeman, Tom McCarthy, John R. Grainger, et al.

    Th17 cells can adopt different functional capabilities in response to environmental stimuli, exhibiting functional plasticity, contributing to both pathogenic autoinflammation but also vital homeostatic immune regulation, particularly at mucosal barriers. However, the upstream signals regulating Th17 cell plasticity and stability remain to be fully outlined. Here, we examined whether the cytokine TGFβ contributed to Th17 cell functional capabilities following differentiation. We utilized an IL‐17A‐specific cre to delete TGFβ receptor II in IL‐17‐producing cells, alongside fate‐mapping cre‐positive cells, to ascertain the role of TGFβ in supporting Th17 cell activity. TGFβR‐deficient Th17 cells were expanded at both mucosal barriers and within lymphoid tissues. However, contrasting previous studies, we show that in both steady state and following induction of inflammation, TGFβR‐deficient Th17 cells remain incredibly stable. We show that TGFβR‐deficient Th17 cells still predominantly produce IL‐17A, express the canonical Th17 cell transcription factor RORγt, and exhibit no altered capacity to produce additional cytokines, indicating TGFβ plays a redundant role in limiting or tailoring the activity of differentiated Th17 cells. However, upon transfer into a lymphopenic environment, TGFβR‐deficient Th17 cells exhibit substantive instability compared to TGFβR‐sufficient control cells, dramatically increasing IFNγ and reducing IL‐17A production, transdifferentiating into Th1‐like exTh17 cells. Thus, our data provide crucial insights into the importance of TGFβ in tailoring Th17 cells, refining our understanding to demonstrate that in lymphocyte‐replete hosts, even in the presence of inflammatory signals, TGFβ plays a limited role in maintaining Th17 cell phenotypes.

  • Open Access

    CD200R1 is required for the development of γδ17 T cells

    by Holly Linley, Shafqat Jaigirdar, Lucy Buckingham, Joshua Cox, Megan Priestley, Anna Hains, Amy Saunders

    γδ T cells are enriched at barrier sites such as skin, gut and lung, where they protect against cancer and infections and promote healing. They detect diverse ligands in T cell receptor-dependent or independent manners, producing large quantities of pro-inflammatory cytokines. γδ T cells develop in foetal thymi in temporally controlled waves where, unlike αβ T cells, many γδ T cells adopt their effector fate, becoming either IFNγ or IL-17A-producers (γδ17 T cells). CD200R1 suppresses myeloid cell activity but has also been shown to promote innate lymphoid cell IL-17A production, enhancing psoriasis-like skin inflammation. γδ17 T cells are potent IL-17A producers in skin therefore, the effect of CD200R1 on IL-17A production by γδ17 T cells was investigated. CD200R1 was found to promote IL-17A production by γδ T cells by supporting the development of γδ17 T cells, enhancing IL-17-producing and RORγt + γδ T cell numbers in foetal thymic organ cultures. To fulfil this role, CD200R1 acts either directly on developing γδ T cells, or indirectly on thymic stromal cells. This identifies CD200R1 as a critical novel regulator of γδ17 T cell development in early life, a key process for ensuring immunity, particularly at barrier sites.


  • Open Access

    Bite-sized immunology; damage and microbes educating immunity at the gingiva

    by Joanne E. Konkel, Joshua R. Cox, Kelly Wemyss


  • Open Access

    Th17-to-Tfh plasticity during periodontitis limits disease pathology

    by Flora A. McClure, Kelly Wemyss, Joshua R. Cox, Hayley M. Bridgeman, Ian E. Prise, James I. King, Shafqat Jaigirdar, Annie Whelan, Gareth W. Jones, John R. Grainger, et al.

    Th17 cell plasticity is crucial for development of autoinflammatory disease pathology. Periodontitis is a prevalent inflammatory disease where Th17 cells mediate key pathological roles, yet whether they exhibit any functional plasticity remains unexplored. We found that during periodontitis, gingival IL-17 fate-mapped T cells still predominantly produce IL-17A, with little diversification of cytokine production. However, plasticity of IL-17 fate-mapped cells did occur during periodontitis, but in the gingiva draining lymph node. Here, some Th17 cells acquired features of Tfh cells, a functional plasticity that was dependent on IL-6. Notably, Th17-to-Tfh diversification was important to limit periodontitis pathology. Preventing Th17-to-Tfh plasticity resulted in elevated periodontal bone loss that was not simply due to increased proportions of conventional Th17 cells. Instead, loss of Th17-to-Tfh cells resulted in reduced IgG levels within the oral cavity and a failure to restrict the biomass of the oral commensal community. Thus, our data identify a novel protective function for a subset of otherwise pathogenic Th17 cells during periodontitis.


  • Open Access

    CD200R1 promotes IL-17 production by ILC3s, by enhancing STAT3 activation

    by Holly Linley, Alice Ogden, Shafqat Jaigirdar, Lucy Buckingham, Joshua Cox, Megan Priestley, Amy Saunders

    Psoriasis is a common chronic inflammatory skin disease with no cure. It is driven by the IL-23/IL-17A axis and T H 17 cells but, recently group 3 innate lymphoid cells (ILC3s) have also been implicated. However, the development, and factors regulating the activity of ILC3s remain incompletely understood. Immune regulatory pathways are particularly important at barrier sites such as the skin, gut and lung, which are exposed to environmental substances and microbes. CD200R1 is an immune regulatory cell surface receptor which inhibits proinflammatory cytokine production in myeloid cells. CD200R1 is also highly expressed on ILCs, where its function remains largely unexplored. We previously observed reduced CD200R1 signalling in psoriasis skin, suggesting that dysregulation may promote disease. Here we show that contrary to this, psoriasis models are less severe in CD200R1-deficient mice due to reduced IL-17 production. Here we uncover a key cell-intrinsic role for CD200R1 in promoting IL-23-driven IL-17A production by ILC3s, by promoting STAT3 activation. CD200R1 is expressed on ILC precursors and is particularly high on neonatal ILC3s, suggesting CD200R1 may function during ILC development. Therefore, CD200R1 is required on ILC3s, potentially during their development, to promote IL-23-stimulated STAT3 activation triggering optimal IL-17 production.